Ananda Basu and Rita Basu
ABOUT THE LAB
The Integrated Carbohydrate Physiology and Translation Laboratory of Ananda Basu, M.B.B.S., M.D., and Rita Basu, M.D., focuses on understanding the integrative physiology of glucose metabolism in people with diabetes and people without diabetes.
The Integrated Carbohydrate Physiology and Translation Lab, which is based at the University of Virginia, has several diabetes-related research interests, including:
- The pathophysiology of prediabetes, type 1 diabetes, type 2 diabetes and hypoglycemia
- The role of excess cortisol and carotid bodies in regulating blood glucose in people with and without diabetes
- The biology of metabolic syndrome
- Understanding subcutaneous glucose transport and continuous subcutaneous glucose sensing in type 1 diabetes
- Accelerating closed-loop control for the development of an artificial pancreas for type 1 diabetes that will deliver insulin automatically and with an individualized precision never before possible
The long-term goal of the research team of Drs. Ananda Basu and Rita Basu is to develop rational and effective therapies for the treatment and prevention of diabetes mellitus and its associated complications.
The Integrated Carbohydrate Physiology and Translation Lab research team uses stable and radioactive isotopes, organ catheterization (hepatic, leg and forearm) and mathematical models to answer research questions.
The team assesses the impact of physiological changes in glucose, insulin, glucagon, cortisol, incretins and various substrates (such as free fatty acids) on carbohydrate, fat and protein metabolism in people with diabetes and people without diabetes.
This line of investigation was pioneered by Robert A. Rizza, M.D., of Mayo Clinic. In the late 1970s and early 1980s, Dr. Rizza conducted experiments with inpatient clinical research-based IV insulin Biostator — the first artificial pancreas.
The Integrated Carbohydrate Physiology and Translation Lab also studies novel aspects of type 2 diabetes and prediabetes.
Research is directed at developing physiological models to inform, fine-tune and eventually personalize an effective closed-loop control artificial pancreas system for patients with type 1 diabetes using cutting-edge insulin pump and glucose sensor technologies.
Other programs are related to defining the role of carotid bodies in the regulation of blood glucose in humans with and without diabetes and obstructive sleep apnea, and the role of cortisol in modulating liver glucose metabolism in obesity and diabetes.